Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
8,908
archived clinical trials in
Renal Impairment / Chronic Kidney Disease

Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
Safety and Efficacy of Treatment With Ultra-low Dose Subcutaneous IL-2 to Promote Regulatory T Cells Post Renal Transplantation
Status: Enrolling
Updated:  7/17/2017
Brigham and Women's Hospital
mi
from
New Boston, NH
Ultra-low Dose Subcutaneous IL-2 in Renal Transplantation
Safety and Efficacy of Treatment With Ultra-low Dose Subcutaneous IL-2 to Promote Regulatory T Cells Post Renal Transplantation
Status: Enrolling
Updated: 7/17/2017
Brigham and Women's Hospital
mi
from
New Boston, NH
Click here to add this to my saved trials
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Status: Enrolling
Updated:  7/18/2017
Columbia University Medical Center
mi
from
New York, NY
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Status: Enrolling
Updated: 7/18/2017
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Status: Enrolling
Updated:  7/18/2017
Weill Cornell Medical Center
mi
from
New York, NY
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Using mTOR Inhibitors in the Prevention of BK Nephropathy
Status: Enrolling
Updated: 7/18/2017
Weill Cornell Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
World Trade Center (WTC) RENAL
Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment
Status: Enrolling
Updated:  7/25/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
World Trade Center (WTC) RENAL
Renal and Cardiovascular Impairment in WTC Responders: Implications for Diagnosis and Treatment
Status: Enrolling
Updated: 7/25/2017
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
A Representational Intervention to Promote Preparation for End-of-life Decision Making
A Randomized Controlled Trial of SPIRIT: A Representational Intervention to Promote Preparation for End-of-Life Decision Making
Status: Enrolling
Updated:  7/28/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
A Representational Intervention to Promote Preparation for End-of-life Decision Making
A Randomized Controlled Trial of SPIRIT: A Representational Intervention to Promote Preparation for End-of-Life Decision Making
Status: Enrolling
Updated: 7/28/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging
Status: Enrolling
Updated:  8/1/2017
Radiology Consultants, Inc.
mi
from
Youngstown, OH
Evaluation of Nephrogenic Systemic Fibrosis (NSF) in Patients With Chronic Kidney Disease Following OptiMARK Injection
A Prospective Study for the Detection of Nephrogenic Systemic Fibrosis in Patients With Renal Impairment Undergoing Gadoversetamide-enhanced Magnetic Resonance Imaging
Status: Enrolling
Updated: 8/1/2017
Radiology Consultants, Inc.
mi
from
Youngstown, OH
Click here to add this to my saved trials
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
Status: Enrolling
Updated:  8/2/2017
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
Status: Enrolling
Updated: 8/2/2017
University of Miami, Division of Clinical Pharmacology
mi
from
Miami, FL
Click here to add this to my saved trials
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
Status: Enrolling
Updated:  8/2/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
A Single Dose Evaluation of the Effects of Renal Impairment on Deflazacort Pharmacokinetics
Status: Enrolling
Updated: 8/2/2017
Orlando Clinical Research Center
mi
from
Orlando, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated:  8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
An Open-Label Study to Determine the Safety and Pharmacokinetics of AT1001 in Subjects With Impaired Renal Function and Healthy Subjects With Normal Renal Function (AT1001-015)
Status: Enrolling
Updated: 8/2/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated:  8/3/2017
GSK Investigational Site
mi
from
Miramar, FL
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated: 8/3/2017
GSK Investigational Site
mi
from
Miramar, FL
Click here to add this to my saved trials
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated:  8/3/2017
GSK Investigational Site
mi
from
Orlando, FL
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated: 8/3/2017
GSK Investigational Site
mi
from
Orlando, FL
Click here to add this to my saved trials
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated:  8/3/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Observational Pharmacokinetic Study Of GW679769 In Subjects With Renal Impairment
An Open-Label, Non-Randomized, Pharmacokinetic and Safety Study of Multiple Oral Doses of GW679769 in Subjects With Renal Impairment
Status: Enrolling
Updated: 8/3/2017
GSK Investigational Site
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Winship Cancer Institute at Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Kansas Cancer Center - Clinical Research Center
mi
from
Fairway, KA
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Maryland
mi
from
Baltimore, MD
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mount Sinai Hospital
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Oklahoma Peggy and Charles Stephenson Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Sarah Cannon Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Mary Crowley Cancer Research Centers - Medical City
mi
from
Dallas, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
Institute of Oncology Hematology Biomedical Research LLC
mi
from
Laredo, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
Institute of Oncology Hematology Biomedical Research LLC
mi
from
Laredo, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University of Texas Health Science Center at San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated:  8/4/2017
University Health Network
mi
from
Toronto,
Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Phase 1/1b Pharmacokinetics Study of Oral Ixazomib (MLN9708) in Relapsed/Refractory Multiple Myeloma and Advanced Solid Tumors Patients With Normal Renal Function or Severe Renal Impairment
Status: Enrolling
Updated: 8/4/2017
University Health Network
mi
from
Toronto,
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
University of California San Diego Medical Center
mi
from
San Diego, CA
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
San Diego Veterans Administration Hospital
mi
from
San Diego, CA
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
San Diego Veterans Administration Hospital
mi
from
San Diego, CA
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
Kansas University Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
New York Methodist Hospital
mi
from
Brooklyn, NY
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
Virginia Commonweath University Medical Center
mi
from
Richmond, VA
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
Virginia Commonweath University Medical Center
mi
from
Richmond, VA
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
Henry Ford Health System
mi
from
Detroit, MI
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
Henry Ford Health System
mi
from
Detroit, MI
Click here to add this to my saved trials
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated:  8/5/2017
Athens University Hospital Attikon
mi
from
Athens,
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin Evaluation of Symptomatic Heart Failure Study
Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin (N-GAL) Evaluation of Symptomatic Heart Failure Study (AKINESIS)
Status: Enrolling
Updated: 8/5/2017
Athens University Hospital Attikon
mi
from
Athens,
Click here to add this to my saved trials
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status: Enrolling
Updated:  8/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease (CKD)
A Phase II, Open-label Safety and Efficacy Study of an Autologous Neo-Kidney Augment (NKA) in Patients With Type 2 Diabetes and Chronic Kidney Disease
Status: Enrolling
Updated: 8/7/2017
University of North Carolina at Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
University of Miami / Cedars Medical Center
mi
from
Miami, FL
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
University of Miami / Cedars Medical Center
mi
from
Miami, FL
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
St. Joseph's Hospital
mi
from
Atlanta, GA
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
St. Joseph's Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Southern Illinois University
mi
from
Springfield, IL
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Southern Illinois University
mi
from
Springfield, IL
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
North Memorial Medical Center
mi
from
Robbinsdale, MN
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
North Memorial Medical Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Bamberg County Hospital
mi
from
Bamberg, SC
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Bamberg County Hospital
mi
from
Bamberg, SC
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Baptist Medical Center
mi
from
San Antonio, TX
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Baptist Medical Center
mi
from
San Antonio, TX
Click here to add this to my saved trials
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated:  8/7/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
HeRO Vascular Access Device Bacteremia Study
HeRO Vascular Access Device Bacteremia Study
Status: Enrolling
Updated: 8/7/2017
Sentara Heart Hospital
mi
from
Norfolk, VA
Click here to add this to my saved trials
Intervention to Reduce Dietary Sodium in Hemodialysis
Intervention to Reduce Dietary Sodium in Hemodialysis
Status: Enrolling
Updated:  8/14/2017
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Intervention to Reduce Dietary Sodium in Hemodialysis
Intervention to Reduce Dietary Sodium in Hemodialysis
Status: Enrolling
Updated: 8/14/2017
University of Pittsburgh School of Medicine
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
UCLA
mi
from
Los Angeles, CA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
UCLA
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Florida
mi
from
Jacksonville, FL
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Iowa
mi
from
Iowa City, IA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
University of Maryland
mi
from
Baltimore, MD
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Massachusetts General Hospital
mi
from
Boston, MA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Beth Isreal Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Baystate Medical Center
mi
from
Springfield, MA
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Baystate Medical Center
mi
from
Springfield, MA
Click here to add this to my saved trials
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated:  8/29/2017
Henry Ford Hospital
mi
from
Detroit, MI
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
A Multi-Center, Randomized, Controlled, Pivotal Study To Assess the Safety and Efficacy of A Selective Cytopheretic Device (SCD) In Patients With Acute Kidney Injury (AKI)
Status: Enrolling
Updated: 8/29/2017
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials